Literature DB >> 1660270

Effects of the enantiomers of lansoprazole (AG-1749) on (H+ + K+)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells.

H Nagaya1, N Inatomi, A Nohara, H Satoh.   

Abstract

The effects of the enantiomers of 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]-sulfinyl ]- 1H-benzimidazole (lansoprazole, AG-1749) on acid formation in isolated canine parietal cells and (H+ + K+)-ATPase activity in canine gastric microsomes were investigated. Both the (+)-and the (-)-enantiomer of lansoprazole inhibited the acid formation stimulated by dibutyryl cyclic AMP (db-cAMP) in isolated canine parietal cells in a concentration-dependent manner with IC50 values of 59 and 82 nM, respectively. The enantiomers showed concentration-dependent inhibition of (H+ + K+)-ATPase with IC50 values of 4.2 and 5.2 microM, respectively. On the other hand, the IC50 values of lansoprazole for db-cAMP-stimulated acid formation and (H+ + K+)-ATPase were 59 nM and 2.1 microM, respectively. These results suggest that the two enantiomers of lansoprazole have antisecretory action due to inhibition of (H+ + K+)-ATPase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1660270     DOI: 10.1016/0006-2952(91)90584-r

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.

Authors:  Z Hussein; G R Granneman; D Mukherjee; E Samara; D L Hogan; M A Koss; J I Isenberg
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.

Authors:  Masatomo Miura; Hitoshi Tada; Norio Yasui-Furukori; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi; Toshio Suzuki
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

Review 3.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 4.  Pharmacokinetics of proton pump inhibitors in children.

Authors:  Catherine Litalien; Yves Théorêt; Christophe Faure
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects.

Authors:  Chise Kodaira; Mitsushige Sugimoto; Masafumi Nishino; Mihoko Yamade; Naohito Shirai; Shinya Uchida; Mutsuhiro Ikuma; Shizuo Yamada; Hiroshi Watanabe; Akira Hishida; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2009-02-24       Impact factor: 2.953

6.  Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.

Authors:  M Miura; H Tada; N Yasui-Furukori; T Uno; K Sugawara; T Tateishi; T Suzuki
Journal:  Eur J Clin Pharmacol       Date:  2004-09-23       Impact factor: 2.953

Review 7.  Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.

Authors:  L B Barradell; D Faulds; D McTavish
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

8.  The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits.

Authors:  Salim M A Bastaki; Irwin S Chandranath; Jaipaul Singh
Journal:  Mol Cell Biochem       Date:  2007-11-28       Impact factor: 3.396

9.  Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000.

Authors:  Adam J Smolka; James R Goldenring; Sandeep Gupta; Charles E Hammond
Journal:  BMC Gastroenterol       Date:  2004-02-10       Impact factor: 3.067

10.  Cytoprotective effect of benzyl N'-(5-chloro-indol-3-yl-methylidene)-hydrazinecarbodithioate against ethanol-induced gastric mucosal injury in rats.

Authors:  Harita Hashim; Fathi F Mughrabi; Mahmood Ameen; Hamid Khaledi; Hapipah M Ali
Journal:  Molecules       Date:  2012-08-03       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.